Long-Term Safety of Etanercept

Gottlieb AB Matheson RT Lowe N . A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–32.

Leonardi CL Powers JL Matheson RT . Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–22.

Papp KA Tyring S Lahfa M . A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.

Dinarello CA . Anticytokine therapeutics and infections. Vaccine 2003;21:S24–34.

Deepe GS Jr Smelt S Louie JS . Tumor necrosis factor inhibition and opportunistic infections. Clin Infect Dis 2005:41 Suppl 3:S187.

Amgen Canada Inc. Enbrel [product monograph]. May 2006.

US Food and Drug Administration. Arthritis Advisory Committee Meeting March 2003. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/03/transcripts/3930T1.htm (accessed March 2007).

Furberg CD Levin AA Gross PA . The FDA and Drug Safety. Arch Intern Med 2006;166:1938–42.

Keystone EC . Safety of biologic therapies—an update. J Rheumatol 2005;32 Suppl 74:8–12.

Listing J Strangfeld A Kary S . Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403–12.

Wallis RS Broder MS Wong JY . Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261–5.

Wallis RS Broder M Wong J Beenhouwer D . Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004;39:1254–5.

Wolfe F Michaud K Anderson J Urbansky K . Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372–9.

Gomez-Reino JJ Carmona L Valverde VR . Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122–7.

Abbott Laboratories. Advisory Committee briefing document: Humira (adalimumab). Abbott Park (IL): Abbott Laboratories; 2003. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/03/briefing/3930B1_02_A-Abbott-Humira.pdf (accessed March 2007).

Mohan AK Cote TR Block JA . Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295–9.

Emery P Panayi G Symmons D Brown G . Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: The role of protein energy malnutrition. Ann Rheum Dis 1984;43:430–4.

Mow WS Abreu-Martin MT Papadakis KA . High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309–13.

Mohan N Edwards ET Cupps TR . Demyelination occurring during anti-tumor necrosis factor-alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862–9.

Robinson WH Genovese MC Moreland LW . Demyelinating and neurologic events reported in association with tumor necrosis factor-alpha antagonism. Arthritis Rheum 2001;44:1977–83.

Lenercept MS Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized placebo-controlled multicenter study. Neurology 1999;53:457–65.

Van Oosten BW Barkoff F Truyen L . Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531–4.

Sukal SA Nadiminti L Granstein RD . Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006;54:160–4.

Berthelot CN George SJ Hsu S . Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 2005;53(5 Suppl 1):S260–2.

Mohan N Edwards ET Cupps TR . Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy [abstract]. American College of Rheumatology 64th Annual Scientific Meeting; 2000 October 28–November 2; Philadelphia, PA.

Enayati PJ Konstantinos AP . Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005;39:303–6.

Jarand J Zochodne DW Martin LM . Neurological complications of infliximab. J Rheumatol 2006;33:1–3.

Midgard R Gronning M Riise T . Multiple sclerosis and chronic inflammatory disease: A case-control study. Acta Neurol Scand 1996;93:322–8.

Annunziata P Morana P Giorgio A . High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort. Acta Neurol Scand 2003;108:327–31.

Kwon HJ Cote TR Cuffe MS . Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807–11.

Feldman AM Combes A Wagner D . The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537–44.

Anker SD Coates AJS . How to recover from Renaissance? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123–30.

Coletta AP Clark AL Banarjee P Cleland JGF . Clinical trials update: RENEWAL, (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559–61.

Chung ES Packer M Lo KH . Randomized double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133–40.

Abbott Laboratories. Humira [product monograph]. 2005.

Schering Canada Inc. Remicade [product monograph]. 2005.

Wolfe F Michaud K . Heart failure in rheumatoid arthritis: Rates, predictors and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305–11.

Gonzalez-Juanatey C Testa A Garcia-Castelo A . Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2004;51:447–50.

del Rincon I Williams K Stern MP . High incidence of cardiovascular events in a rheumatoid arthritis not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.

Book C Saxne T Jacobsson LTH . Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005;32:430–4.

Michaud K Wolfe F . Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate [abstract]. American College of Rheumatology 69th Annual Scientific Meeting; 2005 November 12–17; San Diego, CA.

Mallbris L Akre O Granath F . Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225–30.

Furst ED Breedveld FC Kalden JR . Updated consensus statement on biological agents, specifically tumour necrosis factor (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64:iv2–14.

Wolfe F Michaud K Gilmer K . No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis [abstract]. Ann Rheum Dis 2004;63 Suppl 1:199.

Menon KVN Stadheim L Kamath PS . A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255–60.

Health Canada. Health Canada endorsed important safety information on anti-TNF-alpha therapy: ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infliximab). January 13, 2006. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/index_e.html (accessed January 2007).

Zein N , Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315–22.

Askling J Fored CM Brandt L . Risk of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 2005;64:1421–6.

Margolis D Bilker W Hennessy S . The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778–83.

Stone JH . Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351–61.

Bongartz T Sutton AJ Sweeting MJ . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275–85.

Hawkins-Holt M Hochberg MC Cohen SB . Therapy with biologic agents is not associated with an increased risk of cancer recurrence in patients with rheumatoid arthritis [abstract]. American College of Rheumatology 67th Annual Scientific Meeting; 2003 October 23–28; Orlando, FL.

Gridley G McLaughlin JK Ekbom A . Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307–11.

Mellemkjaer L Linet MS Gridley G . Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753–7.

Isomaki HA Hakulinen T Joutsenlahti U . Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691–6.

Baecklund E Ekbom A Sparen P . Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. Br Med J 1998;317:180–1.

Matteson EL Hickey AR Maguire L . Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in DMARD registry. J Rheumatol 1991;18:809–14.

Ekstrom K Hjalgrim H Brandt L . Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963–70.

Aithal GP Mansfield JC . Review article: The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001;15:1001–108.

Gelfand JM Berlin J Van Voorhees A . Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139;1425–9.

Baecklund E Iliadou A Askling J . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692–701.

Askling J Fored CM Baecklund E . Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414–20.

Cush JJ . Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus. Clin Exp Rheumatol 2004:22 Suppl 35:S141–7.

De Bandt M Sibilia J Le Loet X . Systemic lupus erythematosus induced by anti tumour necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 2005;7:R545–51.

Elkayam O Burke M Vardinon N . Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005;38:155–60.

Eriksson C Engstrand S Sundqvist KG . Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis 2005;64:403–7.

Haraoui B Keystone E . Musculosketal manifestations and autoimmune disease related to the new biologic agents. Curr Opin Rheumatol 2006;18:96–100.

De Rycke L Baeten D Kruitof E . Infliximab but not etanercept induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity. Arthritis Rheum 2005;52:2192–201.

Doran MF Crowson CS Pond GR . Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 2002;46:2287–93.